FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
9 letters match. Newest first.
-
DrugsMaria A. Carballosa, M.D.
FDA warns Dr. Maria Carballosa over failure to retain clinical trial records for an investigational drug.
Medium -
BiologicsAmy Lightner, MD
FDA warns sponsor-investigator Amy Lightner, MD over clinical trial violations, including dosing before eligibility tests and unreported serious adverse events.
High risk -
DrugsMehran Michael Bahrami, M.D.
FDA warns clinical investigator Dr. Mehran Michael Bahrami over protocol violations and missing records in investigational drug trials.
High risk -
BiologicsKonrad Rejdak, M.D., Ph.D.
FDA warns Dr. Konrad Rejdak over clinical trial data integrity failures in a CIDP immune globulin study.
Medium -
DrugsCipla Limited
FDA warned Cipla about unresolved albuterol inhaler delivery complaints and contamination in sterile manufacturing at its Indore site.
High risk -
DevicesAbbott Point of Care Canada Limited
FDA says Abbott Point of Care Canada marketed modified i-STAT cTnI cartridges without required FDA clearance.
High risk -
BiologicsValley Biosystems
FDA cited Valley Biosystems, a California biologics testing lab, for Good Laboratory Practice violations that call its nonclinical study data into question.
High risk -
DrugsVasyl Melnyk, M.D.
FDA warns Dr. Vasyl Melnyk that he lost required records for an investigational drug trial.
Medium -
DrugsKDunn and Associates, P.A. dba HealthQuilt
Houston research sponsor ran a COVID-19 drug study on people without an FDA-approved application or proper consent forms.
High risk